BMIP, launched by government, will function complimentary to international insurers as its global recognition requires time ...

Publication demonstrates how complementary IVUS and OCT information supports lesion assessment, treatment planning, and stent optimization while helping manage contrast use ...

Cemdisiran, a potential new drug for the treatment of generalized myasthenia gravis, has been accepted for priority review by ...

These statements have not been evaluated by the Food and Drug Administration. Memocept is not intended to diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional ...